Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
|Articles|October 18, 2021
The Mainstream Patient: October 18, 2021
Author(s)Linda Stocum, Associate Editor
This week’s edition of The Mainstream Patient features stories about how biologic treatments changed 6 psoriasis patients lives, updated sunscreen regulations, and more!
Advertisement
In this week’s edition, Self tells the story of 6 people with psoriasis who had biologics change their life and New Beauty explains the newest sunscreen regulations from the FDA. Also, Vogue explores if consumers really need a skincare fridge and Elle asks the question should I see an Esthetician or Dermatologist. Finally, Hello Giggles features a dermatologist who explains who face toner should or should not be used and Allure identifies the difference between acne on the lip and a cold sore.
The FDA Just Updated Its Sunscreen Regulations, and This Is Everything a Consumer Should Know
Do You Actually Need A Skincare Fridge?
Esthetician or Dermatologist: Who Should I See?
Are the Pimples on Your Lip Actually a Cold Sore?
Advertisement
Related to this article
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
2
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5